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 LC-MS/MS method for simultaneous
quantiﬁcation of estrogens and their
bioactive metabolites in human
plasma.
 High recoveries and reduced matrix
effects using MCX-SPE® extraction
cartridges followed by MPPZ
derivatization.
 Generation of stable derivatives
allowing quantiﬁcation of estrogens
in low endogenous levels.
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a b s t r a c t
Estrogens regulate many diverse biological processes in health and disease. They circulate at a wide range
of concentrations in females generating several active metabolites (hydroxy and methoxyestrogens). The
metabolites are assumed to be present in much lower levels and are thought to contribute to diseases
such as pulmonary arterial hypertension (PAH). Estrogen metabolites are challenging to quantify in
plasma and currently available immunoassays are non-speciﬁc. Here we have developed and validated a
novel assay to simultaneously quantify parent estrogens and their metabolites by mass spectrometry
(MS).
Estrogens were extracted from human plasma using solid phase extraction and derivatized using 1-(5-
ﬂuoro-2, 4-dinitrophenyl)-4-methylpiperazine (PPZ) before quaternization by methylation (“MPPZ”).
MPPZ derivatives were separated and quantiﬁed by liquid chromatography tandem MS (LC-MS/MS) in
positive electrospray ionization mode, using a QTrap 6500 þ coupled to a Shimadzu Nexera X2. Sepa-
ration was achieved using an ACE Excel 2 C18-PFP column (2 mm, 2.1 mm  150 mm). The limits of
Abbreviations: CID, collision-induced dissociation; cps, counts per second; E1, estrone; OHE1/2, hydroxyestr-one/adiol; MeOE1/2, methoxyestr-one/adiol; ESI, electrospray
ionization; FA, formic acid; IS, internal standards; LC-MS, liquid chromatography-mass spectrometry; LC-MS/MS, liquid chromatography tandem mass spectrometry; LODs,
limits of detection; LLOQ/ULOQs, lower/upper limits of quantitation; PPZ, 1-(5-ﬂuoro-2,4-dinitrophenyl)-4-methylpiperazine; MPPZ, methyl-PPZ-; MRM, multiple reaction
monitoring; PAH, pulmonary arterial hypertension; RME, relative mean error; RSD, relative standard deviation; SD, standard deviation; SNR, signal/noise; SPE, solid phase
extraction.
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Estrogen metabolites
Methylpiperazine
quantiﬁcation (LOQ) were 0.43e2.17 pg on column with a linear range from 2 or 10 - 2000 pg mL-1. Intra
and inter-day precision and accuracy were acceptable (<20% at LOQ and <15% above). These derivatives
demonstrated minimal degradation upon short-term storage at 15 C (<20%) and longer term at 20 C
(<20%). Using this approach, estrone (E1) and estradiol (E2) were detected in plasma (0.5 mL) from
healthy women and those with PAH but downstream metabolites 16-hydroxy-E1, 16-hydroxy-E2, 2-
methoxy-E1 and 4-methoxy-E1 were only detected in plasma from diseased patients. These ﬁndings
will next be tested robustly in large patient cohorts.
This novel LC-MS/MS analysis of estrogens and their bioactive metabolites, using MPPZ derivatization,
opens doors for the simultaneous analysis of a panel of estrogens in human plasma, across the endog-
enous range of concentrations encountered in health and disease.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Estradiol and estrone circulate at low pico/femtomolar levels,
ranging between 0.1 and 530 pg mL1 (0.36e1945 pmol L1)
depending on age, sex and menstrual status [1,2]. They are
metabolized by CYP450 enzymes, generating bioactive hydroxy
and methoxy metabolites (Fig. 1A). The amounts of circulating
downstreammetabolites are assumed to be lower, but uncertainty
exists due to a lack of accurate and precise methods for their
measurement in blood [3]. The lack of a suitable analytical method
hampers the investigation of several estrogen sensitive diseases
such as breast cancer, uterine cancers and various cardiovascular
diseases [4,5] where differential estrogen metabolism is thought
to contribute [6,7] to mechanisms underpinning poor patient
prognosis and outcomes [2]. A number of studies have demon-
strated that imbalances in estrogen metabolism results in either
proliferative or anti-proliferative effects in the vasculature
(Fig. 1B) [8,9].
Current methods to quantify circulating levels of estrogens and
their metabolites employ immunoassays such as ELISA, tech-
niques limited by single analyte measurement, cross-reacting
antibodies and batch variability. Therefore, a method to proﬁle
multiple estrogen metabolites simultaneously is in great demand.
Liquid chromatography tandem mass spectrometry (LC-MS/MS)
offers an alternative approach and is gold standard for analysis of
steroids such as glucocorticoids and testosterone [10,11]. With
estrogens being less abundant, methods are more challenging.
Analysis of nascent estrogens has been reported [12] although
derivatization is often required for LC-MS/MS. The major disad-
vantages associated with analyses of underivatized steroids are
the extended extraction protocols employed to improve signal to
noise and the large sample volumes required [4,5]. Derivatization
improves sensitivity by addition of a permanently or readily-
charged group, allowing higher ionization efﬁciency and
increased sensitivity by MS. In turn this permits shorter extraction
protocols and smaller sample volumes [14]. Derivatization
methods commonly reported for analysis of E1 and E2 include use
of dansyl chloride, N-methyl-nicotinic acid N-hydroxysuccinimide
ester [15], 2-ﬂuoro-1-methylpyridinium-p-toluenesulfonate [16]
and isomers of 1,2-dimethylimidazole-sulfonyl chloride [17,18].
From these, dansyl chloride is most common [13,14,19,20], and its
use has been extended to the downstream metabolites. However
speciﬁcity of the assay for isobaric species is impeded since the
product ions generated are identical for all estrogens, as they hail
from the derivative [19e21]. Furthermore, dansylated products
are light sensitive and the by-products of derivatization can
interfere with analyses [22]. Therefore, alternative derivatization
approaches should be explored.
Herewe have validated a sensitive, speciﬁc and robust analytical
method capable of detecting estrogens and their metabolites in
human plasma. The method employed solid phase extraction (SPE)
and methyl piperazine (MPPZ) derivatization, in conjunction with
LC-MS/MS.
2. Materials and methods
2.1. Standards and solvents
Estrone (E1), 17b-estradiol (17bE2), 17a-estradiol (17aE2), 16-
hydroxyestrone (16OHE1), 16-hydroxyestradiol (16OHE2), 2-
methoxyestrone (2MeOE1), 4-methoxyestrone (4MeOE1), 2-
methoxyestradiol (2MeOE2) and 4-methoxyestradiol (4MeOE2)
were from Steraloids, Inc (Newport, USA). Internal standards
2,3,4e13C3-estrone (
13C3-E1), 2,3,4e
13C3-estradiol (
13C3-E2), formic
acid (FA) andmethyl iodide (CH3I;99%) were from Sigma-Aldrich,
Inc. (St. Louis, USA). 2,3,4e13C3-16-hydroxyestradiol (
13C3-16OHE2),
13,14,15,16,17,18-13C6-2-methoxyestrone (
13C6-2MeOE1) and
13,14,15,16,17,18-13C6-4-methoxyestradiol (
13C6-4MeOE2) were
from CK Isotopes Limited (Leicestershire, UK). Certiﬁed estrone
(1mgmL1 in MeOH; 1mL) and 17b-estradiol (1mgmL1 in
CH3CN; 1mL) were from Cerilliant (Sigma Aldrich, Dorset, United
Kingdom). 1-(5-Fluoro-2, 4-dinitrophenyl)-4-methylpiperazine
(PPZ) was from TCI chemicals (Chuo-ku, Tokyo, Japan). HPLC
grade solvents (methanol, acetone, acetonitrile and water) and
LCMS grade (acetonitrile and water) solvents were from Fisher
Scientiﬁc UK Limited (Leicestershire, UK).
2.2. Instrumentation
Analysis was performed on a QTrap 6500þ (Sciex, Warrington,
UK) coupled to a Shimadzu Nexera X2 LC (Kyoto, Japan), operated
using Analyst software v1.5.1.
2.3. Plasma samples
Female human plasma for method development and validation
was from TCS Biosciences (Botolph Claydon, England), aliquots
stored at 20 C. This was prepared from blood of healthy human
donors in approved blood collection centers. Additionally, we
studied plasma from patients with pulmonary arterial hyperten-
sion (PAH) as it has previously been reported that estrogen levels
are elevated in these patients and metabolites may be pathogenic
[2,23,24]. PAH patient samples were collected with ethical approval
within the Scottish Pulmonary Vascular Unit, Golden Jubilee Na-
tional Hospital, Glasgow. The four female patients were as follows;
36 y idiopathic PAH (contraception unknown), 44 y; idiopathic PAH
patient (Mirena® coil), 46 y; idiopathic PAH (desogestrel) and a
55 y; hereditary PAH patient (tamoxifen).
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2.4. Standard solutions
Estrogens (1mg) and internal standards (IS; 1mg) were dis-
solved in methanol (1mL) and stored at 80 C. Working solutions
(0.0001e10 pg mL1) were prepared by serial dilution on the day of
use.
2.5. Generation of MPPZ derivatives
PPZ stock (10 mL; 1 mgmL1), sodium bicarbonate (10 mL; 1M)
and acetone (70 mL) were added to the standard/extract. The solu-
tion was incubated (60 C, 1 h; Reaction 1). Reagents were reduced
to dryness at 40 C under oxygen free nitrogen (OFN). The dried
residue was incubated (40 C, 2 h; Reaction 2) with CH3I (100 mL).
The mixture was reduced to dryness under OFN and dissolved in
H2O/CH3CN (70:30; 70 mL).
2.6. Tuning and fragmentation analysis of MPPZ derivatives of
estrogens and metabolites
The 6500 þ Mass Spectrometer was operated in positive elec-
trospray (ESI) mode as follows: curtain gas (40.0 psi), collision gas
(medium), ion spray (5500 V), temperature (700 C), nebulizer gas
(60.0 psi) and heater gas (40.0 psi). For the detection of product ions
by MS, molecular ions were isolated by their Q1 parent mass and
subjected to collision induced dissociation (CID), in scanning mode
using a range fromm/z 450 to 640. Conditions for multiple reaction
monitoring (MRM) were optimized by auto-tuning during infusion
of the estrogen metabolites and IS (1 mgmL1). The collision energy
for each compound was optimized to achieve maximal sensitivity
to detect quantiﬁer and qualiﬁer ions.
Structures of fragment ions formed from estrogen derivatives
were determined by high resolution MS using a Synapt G2Si
instrument (Waters Corp, Manchester, UK) ﬁtted with an ESI
Fig. 1. Estrogen metabolism; (A) The estrogen metabolism pathway, where parent estrogens, estrone and estradiol, are interchangeable by the action of 17b-HSDs prior to
biotransformation by various cytochrome P450 enzymes inducing hydroxylation reactions in the 20 , 40 or 160 positions to form hydroxyestrogens. Rapid conversion/deactivation of
the 2 and 4 hydroxylated estrogens then occurs via the action of COMT enzyme causing methylation in 20 or 40 positions. (B) Cardiovascular effects of imbalances in estrogen
metabolism on normal cell homeostasis thought to drive both proliferative and antiproliferative cell phenotypes within the vasculature.
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source in positive mode. Samples (0.1 mg mL1) dissolved in H2O:
CH3CN (70:30) were infused 2 mL/min (Harvard Apparatus, UK)
at a spray voltage 3.0 kV, sampling cone voltage 40 V and source
temperature 100 C. Data was collected in full scan mode and
MS2 spectra (m/z 50 - 1200) in resolution mode. Tandem mass
spectra were generated in the trapping region of the ion mobility
cell using collision energy 40 V, with argon as the collision gas
(40.0 psi). Instrument calibration was performed using 0.05M
sodium formate. Lock mass correction was applied to precursor
masses.
2.7. Chromatographic conditions
Estrogen metabolites were analyzed using an Ace Excel 2 C18-
PFP column (150 2.1mm 2 mm; HiChrom, Reading, England). A
gradient solvent system of water: acetonitrile (90:10), containing
FA (0.1%, 0.5mL/min) was diverted to waste for the initial 9min
followed by elution for a further 4min at 90:10, then with a
gradient over 3min until ﬁnal conditions of water: acetonitrile
(90:10) containing FA (0.1%, 0.5mL/min) were achieved. Column
and auto-sampler temperatures were 25 C and 15 C, respectively.
Injection volume was 30 mL.
2.8. Extraction method
Aliquots of female plasma were subject to centrifugation
(8000 g, 4 C, 20min) with the sediment discarded. Sample vol-
umes (0.5mL) were adjusted to 1mL with water and enriched with
internal standards (100 pg). Standard solutions were added into
1mL water. SPE using Oasis® MCX (3 cc/60mg, Waters, Wilmslow,
UK) extraction cartridges was performed under gravity. Prior to
loading the sample, the cartridges were conditioned and equili-
brated with methanol (2mL), followed bywater (2mL). The diluted
sample was loaded and allowed to pass through the cartridges and
the eluate discarded. The cartridges were washed ﬁrst with
aqueous FA (2% v/v, 2mL) and then with MeOH (30% v/v, 2mL) and
eluates discarded. Steroids were eluted in MeOH (100%; 2mL).
Extracts were reduced to dryness under OFN (40 C) and the resi-
dues were derivatized as above.
2.9. Assay validation
2.9.1. Optimization of derivatization conditions
Reaction conditions were optimized ﬁrst using aqueous extracts
and then using extracts of plasma. Conditions evaluated were in-
cubation temperature (Reaction 1; 40e70 C; Reaction 2;
40e60 C), reaction time (Reaction 1; 30e90min; Reaction 2;
30e180min), reaction or reagent volume (Reaction 1; 10e30 mL,
Reaction 2; 40e160 mL) and PPZ concentration (1e3mg mL1).
2.9.2. Extraction efﬁciency
Recoveries of derivatives from water and plasma were assessed
by comparison of mean peak areas of derivatives (1 ng; n¼ 6)
following extraction, in pre-spiked samples divided by those in
post-spiked samples.
2.9.3. Matrix effects
Ion suppression of derivative signals in the presence of extracts
of plasma was evaluated by comparing signal intensity of de-
rivatives post-spiked into extracted plasma with that of aqueous
estrogen solutions of the same concentration (1 ng; n¼ 6)
following derivatization and expressed as a percentage.
2.9.4. Speciﬁcity
Mass chromatograms were inspected at the retention times of
estrogens and IS for interferences by other endogenous compounds
in plasma.
2.9.5. Limit of detection (LOD)
Estrogens (0.0005, 0.001, 0.002, 0.006, 0.01 ng and 0.5, 1, 2, 6,
10 pgmL1) were analyzed by LC-MS/MS and the Signal/Noise
(SNR) calculated. The limits of detection (LOD) were assigned at a
SNR >3.
2.9.6. Linearity
Blank samples and aliquots containing estrogens (1, 2, 6, 10, 20,
40, 100, 200, 500, 1000, 2000 pgmL1) and internal standards
(200 pgmL1) were analyzed by LC-MS/MS. Calibration curves
were plotted as the peak area ratio (standard/IS) versus amount of
estrogens. Calibration lines were tested for lack of ﬁt to a linear
model and considered acceptable if the Fcalculated< Fcritical.
Regression coefﬁcients were deemed acceptable if r was >0.99.
Weightings of equal, 1/x and 1/x2 were evaluated.
2.9.7. Lower limit of quantitation (LLOQ)
Replicate aliquots (0.001, 0.002, 0.01 ng and 1, 2, 10 pgmL1;
n¼ 6) of estrogens and internal standards (0.2 ng; 200 pgmL1)
were analyzed as above. The LLOQ was calculated as that amount
affording precision and accuracy of ~20%.
2.9.8. Accuracy and precision
The intra- and inter-day assay precision and accuracy were
assessed using amounts of standard (2 & 200 or 2000 pgmL1) and
spiked plasma (100 pgmL1 of metabolites only) prepared on the
same day and different days, respectively (n¼ 6). The precision was
calculated as the Relative Standard Deviation (RSD) (standard devi-
ation/mean x 100), and % accuracy was the Relative Mean Error
(RME), ((meanmeasured value - theoretical value)/theoretical value)
x 100); precision and accuracywere acceptedwith RSD/RME<20% at
LLOQ and <15% above. The bias of the calibration was tested against
certiﬁed referencematerial for E1 and 17bE2; Bias, (Average Interday
concentration e reference material concentration).
2.9.9. Stability
Stability following storage in the auto-sampler (15 C) and
freezer (20 and 80 C) was evaluated by reinjection of a cali-
bration standard and plasma sample (200 pgmL1) after 24 h, 4, 8
and 31 days and expressed as % of the initial amount ((Sample Peak
Area/T0 Peak Area) x 100).
2.10. Method application
The presence of estrogens and their metabolites was assessed,
and their amounts quantiﬁed in human plasma from healthy fe-
male pooled controls (n¼ 3) and individual female PAH patients
(n¼ 4) using the validated approach.
3. Result and discussion
3.1. Method development
3.1.1. Development of derivatization approach
All estrogenmetabolites possess phenolic functional groups and
are potential targets for derivatization by aromatic neutrophilic
substitution, with additional ketone and/or hydroxyl groups pre-
sent for estrone and estradiol metabolites, respectively. The
phenolic group in the 30 position of the A ring is most suitable for
derivatization of the entire metabolite panel allowing clear mass
distinction between steroids with ketones (estrone metabolites)
and hydroxyls (estradiol metabolites) in the 17’ position of the D
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Ring. Fig. 2 illustrates the two-step MPPZ reaction with 17b-estra-
diol allowing formation of a permanently positively charged de-
rivative. PPZ is a derivatization agent particularly well suited to
steroid analysis by LC-ESI-MS/MS and has been applied to alter-
native matrices such as serum from pregnant women for
commonly analyzed E1 and E2 but not for the bioactive metabolites
[25]. It reacts rapidly and speciﬁcally with phenols to give 3-O-[2,4-
dinitro-5-(4-methylpiperazino) phenylestrogens. A permanent
positive charge is then appended by subsequent quaternarization
of the piperazine amino group using methyl iodide [26]. Intense
precursor and product ion signals in ESI-MS were observed, with
the anticipated molecular ions of a singly-derivatized species
shown in Table 1 which formed for all standards tested. 2 and 4
-hydroxy estrogens did not react well under these conditions and
were explored separately [27]. Fragmentation patterns of the 9
derivatives (Table 1) were interrogated by accurate mass spec-
trometry (Supplementary Table 1) and putative structures assigned
(Fig. 2), with masses within 10 Dppm of their theoretical values
except in a few cases where signal intensity of fragments was low.
Analyte speciﬁc product ions were assigned for EI and E2, however,
certain metabolites generated similar fragments through the loss of
the derivative function. Quantiﬁer and qualiﬁer ions were assigned
(Table 1), but the common fragments produced by some of the
metabolites led to an absolute need for chromatographic separation
between isotopologues and isobars.
The MPPZ derivatives of E1 and 17bE2 fragmented to give two
speciﬁc product ionsm/z 549/ 502 and 551/504 (Fig. 3) by loss
of NO2. These masses demonstrated an increment of Mþ3 for their
stably labelled counterparts at m/z 505.3 and m/z 507.3, respec-
tively, supporting the presence of the steroidal A ring. Smaller
fragments of m/z 72 and m/z 58 were also formed, lacking stable
isotope functions and common across several of the metabolite
derivatives. These result through loss of [M-C4H10N
þ] and [M-
C3H8N
þ] respectively from the methylated piperazine structure
(Fig. 2, Supplementary Table 1). For methoxyestrogens, product
ions of m/z 280 and 250 were observed, again without mass in-
crements in the labelled species and thus less speciﬁc for analytes.
The difference of unit mass between the fragment ions of m/z 250/
251 and m/z 280/281 between methoxy and hydroxy metabolites
respectively suggests a block to proton migration from the 20 or 4’
position of estrogen due to the methylated group.
Fig. 2. Formation of methylpiperazine (MPPZ) derivative of phenolic estrogens; showing an example of derivatization of 17b-estradiol with 1-(5-ﬂuoro-2,4-dinitrophenyl)-4-
methylpiperazine (PPZ) in the presence of sodium bicarbonate (NaHCO3) followed by reaction with methyl iodide (CH3I) to create the charged moiety.
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3.1.2. Optimization of derivatization reaction conditions
The efﬁciency of the initial PPZ reaction was not improved by
alterations in reaction time, temperature or by reagent volume,
concentration and pH. In the second methylation reaction, the ef-
ﬁciency and reproducibility of derivative formation was improved
by increasing reaction time (30e120 min) and decreasing the re-
action temperature (60e40 C). Additionally, reconstitution of
samples in mobile phase of higher organic proportions (70:30
H2O:CH3CN) improved signal intensities. Additionally, it should be
noted that the use of plastic 96-well microtitre plates for the
analysis of MPPZ-estrogen derivatives is not recommended as
when used inconsistent signal responses for spiked samples were
observed and derivative stability was poorer.
3.1.3. Chromatographic conditions
Chromatographic conditions were assessed on ﬁve LC columns
representing a variety of stationary phases (Acquity Atlantis T3, ACE
Ultra Core Super C18, ACE Excel Super C18, ACE Excel C18-AR and
ACE Excel C18-PFP, all 150mm in length). Separation could not be
achieved on the Acquity Atlantis T3 contained C18 groups on par-
ticle sizes of 3 mm, whereas the small particles of 2.5 mm in the ACE
Ultra Core Super C18 allowed partial but incomplete peak separa-
tion. The ACE Excel Super C18 with its unique encapsulated
bonding technology and ACE Excel C18-AR with its integrated
phenyl capacity chosen for added selectivity for aromatic com-
pounds still did not resolve the methoxyestrogen metabolites. The
ACE Excel C18 with integral pentaﬂuorophenyl functionality added
further selectivity via its p-p interactions and was the only column
able to successfully resolve the methoxyestrogen metabolites
alongside the wider panel, with typical retention times shown in
Table 1.
3.1.4. Extraction
Liquid-liquid extraction of plasma has been applied to recover
estrogens, e.g. using dichloromethane or ethyl acetate, however
manual liquid extraction can lead to imprecision, with cumbersome
protocols and lower recovery rates [28,29]. Extraction of estrogen
and metabolites using Oasis® MCX separation columns with the
manufacturer's generic protocol allowed high recovery (93e108%)
of the 9 target metabolites (Table 2). However, signiﬁcant ion
suppression was identiﬁed when the method was applied to
plasma; signals were typical suppressed to by 56e71%, even
following the 2% FAwash. Ion suppressionwas minimized (Table 2)
by washing with 30% MeOH prior to elution with 100% MeOH.
Alternate conditions for 16aOHE1 and 16aOHE2 applying a 40%
MeOH wash and 95% MeOH elution reduced ion suppression
further (18± 18% and 22± 10%, respectively). This change however
negatively inﬂuenced the quality of data for the other metabolites
and was not pursued for use with the whole panel.
3.2. Assay validation
Validation of the panel of 9 estrogens was progressed.
3.2.1. Speciﬁcity
Baseline chromatographic separation of estrogen derivatives
was achieved in aqueous standards. When applied to plasma
samples, interferences closely eluting at the retention time of each
estrogen were not observed, such as 17a-E2, which displays a
different retention time to 17bE2 (Fig. 4).
3.2.2. Linearity
Stable-isotope labelled estrogens (13C3 and
13C6) were selected
as internal standards, dependent on availability (Table 2). One
Table 1
Liquid Chromatograpy- Tandem Mass Spectrometry: Optimized tune parameters of methylpiperazine derivatives of estrogens and their retention times.
Analyte -
MPPZ
Precursor Ion m/
z
Product Ions m/
z
aQuan
bQual
Collision Energy
(V)
Collision exit cell potential
(V)
De-clustering potential
(V)
Entrance potential
(V)
Retention Time
(mins)
E1 549.0 a502.3 59.0 20.0 141.0 10.0 15.5
b72.0 99.0 12.0 131.0
17aE2 551.0 a504.3 129.0 8.0 166.0 10.0 15.1
b58.1 59.0 20.0 51.0
17bE2 551.0 a504.3 129.0 8.0 166.0 10.0 14.6
b58.1 59.0 20.0 51.0
16OHE1 565.0 a58.0 105.0 10.0 130.0 10.0 13.2
b251.4 59.0 10.0 130.0
16OHE2 567.0 a58.0 121.0 8.0 136.0 10.0 12.1
b251.0 61.0 22.0 166.0
2MeOE1 579.0 a58.0 55.0 12.0 186.0 10.0 15.8
b280.1 121.0 8.0 66.0
4MeOE1 579.0 a280.1 121.0 8.0 66.0 10.0 15.6
b58.0 55.0 12.0 186.0
2MeOE2 581.0 a250.0 57.0 28.0 66.0 10.0 14.9
b58.0 63.0 24.0 111.0
4MeOE2 581.0 a250.0 57.0 28.0 66.0 10.0 14.6
b58.0 63.0 24.0 111.0
13C3-E1 552.3
a505.3 39.0 15.0 39.0 10.0 15.5
b388.2 45.0 15.0 45.0
13C3-E2 554.3
a507.3 35.0 15.0 35.0 10.0 14.6
b390.3 40.0 15.0 40.0
13C3-16OHE2 570.1
a58.1 100.0 15.0 135.0 10.0 12.1
b72.10 100.0 15.0 135.0
13C6-2MeOE1 585.0
a58.1 100.0 15.0 125.0 10.0 15.8
b280.1 100.0 15.0 50.0
13C6-4MeOE2 587.0
a58.1 100.0 15.0 100.0 10.0 14.6
b280.00 100.0 15.0 75.0
Voltage (V); Estrone (E1); estradiol (17 a/b E2); 16-hydroxyestrone (16OHE1); 16-hydroxyestradiol (16OHE2); 2 or 4-methoxyestrone (2 or 4-MeOE1); 2 or 4-
methoxyestradiol (2 or 4-MeOE2); 2,3,4e13C3-estrone (
13C3-E1); 2,3,4e
13C3-estradiol (
13C3-E2); 2,3,4e
13C3-estriol (
13C3-16OHE2); 13,14,15,16,17,18-
13C6-2-
methoxyestrone (13C6-2MeOE1) and 13,14,15,16,17,18-
13C6-4-methoxyestradiol (
13C6-4MeOE2).
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Fig. 3. Proposed fragmentation patterns following accurate mass analysis at 1 mgmL1 of estrogen methylpiperazine derivatives displaying common mass fragments; (A) Estrone (B)
17b- Estradiol (C) 4MeOEl.
N. Denver et al. / Analytica Chimica Acta 1054 (2019) 84e9490
labelled estrogen per chemical grouping was chosen due to cost
constraints but paired internal standards are available for all ana-
lytes and are recommended. Derivatives quantiﬁed with exact
labelled versions for comparison demonstrated a more accurate
response (Table 3). A mean r-value > 0.99 for calibration lines was
achieved for all derivatives with a weighting of 1/x throughout. A
linear relationship was also conﬁrmed as curves also passed lack of
ﬁt tests (Supplemental Table 2). The linear range achieved is similar
to that of methods quantifying E1 and E2 using other sensitive
derivatives developed in the past few years for both plasma [16,30]
and urinary analysis [31].
3.2.3. Limits of detection and quantitation
The LOD and LLOQs for estrogen MPPZ derivatives (Table 2)
measured in standard solutions are comparable to previous
methods for the analysis of E1 and E2 [16,21,32e34]. The volume
of plasma (0.5 mL) extracted by SPE for detection of metabolites
demonstrated an improvement over recent methods for oncology
studies; one study by Yang et al., 2008 used 2mL of patient
serum using a longer extraction protocol where samples were
incubated overnight prior to liquid extraction of estrogens [35].
Another study applied dansyl chloride and achieved low LLOQs of
0.05e0.1 pg on column but required specialized equipment not
commonly available within hospitals and clinical laboratories
[36].
3.2.4. Precision and accuracy
The values for intra- and inter-assay precision and accuracy
Table 2
Extraction efﬁciency, limits of quantitation and linearity of response.
Assessment of the extraction efﬁciency of estrogens from plasma showing high recovery rates and decreased ion suppression upon optimization. Calibration curves over awide
linear range are presented, and the limits of quantitation.
Analyte IS Recovery
(%)
Generic
IonS (%)
Optimized
IonS (%)
LLOD
pg mL1 (pg on column)
LLOQ
pg mL1 (pg on column)
ULOQ
pg mL1 (pg on column)
Mean r
E1 13C3E1 108± 9% - 63± 11% - 9± 19% 1 (0.21) 2 (0.43) 2000 (434.7) 0.998
17aE2 13C3E2 101± 11% - 62± 11% - 6± 18% 2 (0.43) 2 (0.43) 2000 (434.7) 0.990
17bE2 13C3E2 102± 10% - 71± 8% þ 17 ± 8% 1 (0.21) 2 (0.43) 2000 (434.7) 0.993
16OHE1 13C3-16OHE2 111± 10% - 62± 8% - 37± 6% 2 (0.43) 10 (2.17) 2000 (434.7) 0.998
16OHE2 13C3-16OHE2 103± 14% - 69± 5% - 40± 8% 2 (0.43) 10 (2.17) 2000 (434.7) 0.996
2MeOE1 13C6-2MeOE1 98± 10% - 56± 11% - 3± 16% 6 (1.30) 10 (2.17) 2000 (434.7) 0.996
4MeOE1 13C6-2MeOE1 102± 16% - 56± 5% - 11± 15% 6 (1.30) 10 (2.17) 2000 (434.7) 0.996
2MeOE2 13C6-4MeOE2 93± 11% - 59± 4% - 9± 13% 6 (1.30) 10 (2.17) 2000 (434.7) 0.995
4MeOE2 13C6-4MeOE2 98± 15% - 58± 8% - 14± 19% 6 (1.30) 10 (2.17) 2000 (434.7) 0.996
Estrone (E1); estradiol (17 a/b E2); 2, 4 or 16-hydroxyestrone (16OHE1); 16-hydroxyestradiol (16OHE2); 2 or 4-methoxyestrone (2 or 4-MeOE1); 2 or 4-methoxyestradiol (2
or 4-MeOE2); IS ¼ Internal Standard; Recovery¼ Prespike/pospiked estrogen; IonS¼ Ion Suppression¼ Postspike derivatized estrogen/unextracted peak areas;
Generic¼Manufacturer's Protocol; Optimized¼ addition of MeOH wash step; LLOD/Q¼ lower limit of detection/quantitation; ULOQ ¼ Upper level of quantitation; pg mL-1
(pg on column).
Fig. 4. Mass chromatograms of methylpiperazine (MPPZ) derivatives of estrogens and their metabolites following analysis of an extracted solution of Standards, 2000 pg mL-1. Total
Ion Chromatograms and the corresponding extracted ion chromatograms showing resolution of derivatives of estrone (El), estradiol (17a & 17bE2), 16- hydroxyestrogens (16OHE1 &
16OHE2) and methoxyestrogens (2MeOEl, 4MeOEl, 2MeOE2 & 4MeOE2) by retention time and mass transition.
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(Table 3) were acceptable at low points of the calibration curve
(<20%) 0.43 & 2.17 pg on column (2 and 10 pgmL1) and <15%
above this level; 43.4& 434.0 pg on column (200 or 2000 pgmL 1).
Accuracy of calibration data compared favorably with certiﬁed
reference material for E1 and E2 (metabolites not available;
Supplemental Table 3). The bias was higher at ULOQ when a
weighting of 1/x was applied, this could be corrected by removing
this weighting to achieve a better ﬁt at higher concentrations. In
general, we expect the quantiﬁed levels to fall below this point. In
addition, acceptable precision was shown for endogenous E1 and
E2 and for the six metabolites enriched in healthy female plasma
samples (100 pgmL1 metabolites), except for 4MeOE1. The up-
ward deviation may have reﬂected presence of low endogenous
levels of this species.
3.2.5. Stability
The MPPZ derivatives in extracts of standards and plasma
demonstrated suitable stability upon short term storage up to 8
days in the auto sampler (15 C) and upon longer term storage of 31
days in the freezer (20 C), with less than 20% degradation. Stor-
age at lower temperatures (80 C) caused degradation of
methoxyestrogens over the 31 days (50% or upon rethaw), but was
suitable for E1, E2 and 16-OHE1/2 metabolites (Supplementary
Table 4).
3.3. Method application
The method was applied to samples from female pooled con-
trols vs female PAH patient plasma. Calculated concentrations of
estrone and estradiol were compared to reported biological con-
centrations and fall within the expected ranges (E1/17bE2¼ 73.4 e
1725.3 pmol L1) whereas metabolites were only detected in PAH
patient plasma (27.8 - 734.2 pmol L-1) (Fig. 5), albeit only small
numbers of samples were analyzed.
4. Conclusion
In summary, derivatization of estrone, estradiol and six of its
bioactive metabolites by MPPZ derivatization allows quantiﬁcation
to desired levels in patient samples. This approach for plasma
analysis compares favorably with several LC-MS/MS methods
developed for E1 and E2 with comparable sensitivities and an
improved stability of derivatives. Derivatization of this extended
panel of estrogen metabolites for their simultaneous analysis in
plasma has not been available routinely in the past for clinical an-
alyses. This approach offers a novel wider view of estrogen meta-
bolism, which appears highly relevant to estrogen sensitive
diseases and will now be applied to larger cohort studies.
Table 3
Intra-day and inter-day validation.
Summary table of the accuracy and precision data showing acceptable intra-day and inter-day reproducibility. For standards, criteria were met at the LLOQ and ULOQ. For
metabolites the mid concentration is shown rather than ULOQ, as this is more relevant to expected levels. For plasma, validation was performed in aliquots containing
endogenous estrone and estradiol and enriched with metabolites.
Metabolite Target
(pg mL1)
Intraday (n¼ 6) Interday (n¼ 6)
Mean
(pg mL1)
Precision
(RSD %)
Accuracy
(RME %)
Mean
(pg mL1)
Precision
(RSD %)
Accuracy
(RME %)
E1 2 2.2 8.7 7.4 2.0 8.0 0.3
2000 2464 14.0 14.1 2232 13.9 6.1
Endogenous 37 13.3 e 31 13.1 e
17aE2 2 2.1 10.6 5.0 1.9 12.1 1.6
2000 2210 11.2 10.6 2280 6.7 13.9
Endogenous ND e e ND e e
17bE2 2 2.1 7.6 4.2 2.0 7.6 3.6
2000 2244 11.5 6.1 1864 12.1 5.3
Endogenous 24 13 e 28 12.4 e
16OHE1 10 9.3 3.9 7.4 10.0 1.4 1.8
200 228 9.4 14.4 196 9.7 1.7
Plasma þ 100 96 6.9 4.8 101 11.8 1.2
16OHE2 10 9.7 5.0 3.2 10.1 1.5 1.8
200 202 7.4 7.4 194 9.9 3.4
Plasma þ 100 112 4.1 12 104 4.2 4.6
2MeOE1 10 9.4 10.0 4.1 10.2 9.4 1.5
200 176 10.6 12.2 203 5.6 3.4
Plasma þ 100 114 4.1 12.0 104 6.3 2.7
4MeOE1 10 10.1 2.7 11.8 9.7 5.7 1.2
200 220 13.3 8.6 202 6.9 1.6
Plasma þ 100 108 11.5 7.0 120 14.2 20.7
2MeOE2 10 8.8 4.2 11.7 9.5 7.2 5.2
200 198 14.3 0.8 204 4.1 2.4
Plasma þ 100 108 11.7 7.7 108 14.4 8.5
4MeOE2 10 9.0 5.6 8.8 10.3 2.5 2.6
200 198 8.9 1.0 228 5.9 6.6
Plasma þ 100 104 4.8 3.2 106 9.6 6.6
Estrone (E1); estradiol (17 a/b E2); 16-hydroxyestrone (16 OHE1); 16-hydroxyestradiol (16 OHE2); 2 or 4-methoxyestrone (2 or 4-MeOE1); 2 or 4-methoxyestradiol (2 or 4-
MeOE2); RSD, standard deviation/mean x 100, RME %, Relative Mean Error ((mean measured value - theoretical value)/theoretical value x 100); Endogenous levels in female
plasma; Plasma þ100 (metabolites spiked in plasma at 100 pg mL1). ND¼ not detected.
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